{
  "PMC": "5926053",
  "DOI": "10.1111/j.1349-7006.1999.tb00735.x",
  "PMID": "10189892",
  "PMCID": "PMC5926053",
  "title": "Overexpression of MDM2 in MCF-7 promotes both growth advantage and p53 accumulation in response to estradiol.",
  "year": 1999,
  "source_url": "https://europepmc.org/article/PMC/PMC5926053",
  "source": "MED",
  "abstract_text": "The overexpression of the oncogene product MDM2 is often observed in human breast cancer cells, especially in estrogen receptor (ER)-positive ones. To study the role of MDM2 protein in ER-positive breast cancer, we have established cell lines derived from MCF-7 which stably express increased and decreased levels of MDM2 by transfection of a mammalian expression vector containing human mdm2 cDNA in sense and antisense orientations, respectively. Interestingly, MDM2 overexpression in MCF-7 cells afforded a remarkable growth advantage under estradiol (E2)-supplemented condition. Then, we analyzed the expression of p53, which is an important regulator of growth and the cell cycle. Unexpectedly, the p53 accumulation induced by E2 was remarkably higher in MCF-7 cells stably overexpressing MDM2 than in the parent MCF-7 cells. On the other hand, reduction of MDM2 suppressed the E2-induced increase in p53 protein. Moreover, mdm2 antisense oligonucleotides prevented E2-induced accumulation of p53. In the steady state, the cellular levels of p53 were also correlated with those of MDM2. These interactions are not consistent with the well-known role of MDM2, which acts as a negative regulator for p53 by inhibiting its function and promoting its rapid degradation. These results suggest that MDM2 may regulate the expression of p53 in the steady state and in response to E2 in breast cancer cells, and imply a novel and important role of MDM2 during breast carcinogenesis.",
  "full_text": "Jpn J Cancer Res Jpn. J. Cancer Res 10.1111/(ISSN)1349-7006a CAS Japanese Journal of Cancer Research : Gann 0910-5050 1876-4673 Blackwell Publishing Ltd Oxford, UK 5926053 10189892 10.1111/j.1349-7006.1999.tb00735.x CAE210 Article Overexpression of MDM2 in MCF‐7 Promotes Both Growth Advantage and p53 Accumulation in Response to Estradiol Saji Shigehira 1 Nakashima Shigeru 2 Hayashi Shin‐ichi 3 Toi Masakazu 4 Saji Shigetoyo 1 Nozawa Yoshinori 2 1 2nd Department of Surgery 2 Department of Biochemistry, Gifu University School of Medicine, 40 Tsukasa‐machi, Gifu 500–8705 3 Saitama Cancer Center Research Institute, Ina‐machi, Kitaadachi‐gun, Saitama 362–0806 4 Department of Surgery, Tokyo Metropolitan Komagome Hospital, 3–18‐22 Honkomagome, Bunkyo‐ku, Tokyo 113–0021 * To whom correspondence should be addressed. E‐mail: ss-saji@wa2.so-net.ne.jp 2 1999 90 2 10.1111/cas.1999.90.issue-2 210 218 Received October 14, 1998/Revised November 30, 1998/ Accepted December 4, 1998 The overexpression of the oncogene product MDM2 is often observed in human breast cancer cells, especially in estrogen receptor (ER)‐positive ones. To study the role of MDM2 protein in ER‐positive breast cancer, we have established cell lines derived from MCF‐7 which stably express increased and decreased levels of MDM2 by transfection of a mammalian expression vector containing human mdm2 cDNA in sense and antisense orientations, respectively. Interestingly, MDM2 overexpression in MCF‐7 cells afforded a remarkable growth advantage under estradiol (E2)‐sup‐plemented condition. Then, we analyzed the expression of p53, which is an important regulator of growth and the cell cycle. Unexpectedly, the p53 accumulation induced by E2 was remarkably higher in MCF‐7 cells stably overexpressing MDM2 than in the parent MCF‐7 cells. On the other hand, reduction of MDM2 suppressed the E2‐induced increase in p53 protein. Moreover, mdm2 antisense oligonucleotides prevented E 2 ‐induced accumulation of p53. In the steady state, the cellular levels of p53 were also correlated with those of MDM2. These interactions are not consistent with the well‐known role of MDM2, which acts as a negative regulator for p53 by inhibiting its function and promoting its rapid degradation. These results suggest that MDM2 may regulate the expression of p53 in the steady state and in response to E2 in breast cancer cells, and imply a novel and important role of MDM2 during breast carcinogenesis. Breast cancer MDM2 p53 Estrogen receptor source-schema-version-number 2.0 cover-date February 1999 details-of-publishers-convertor Converter:WILEY_ML3GV2_TO_NLMPMC version:4.6.9 mode:remove_FC converted:04.11.2015 REFERENCES 1 ) Cahilly‐Snyder , L. , Yang‐Feng , T. , Francke , U. and George , D. L. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line . Somat. Cell Mol. Genet. , 13 , 235 – 244 ( 1987 ). 3474784 2 ) Fakharzadeh , S. S. , Trusko , S. P. and George , D. L. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line . EMBO J. , 10 , 1565 – 1569 ( 1991 ). 2026149 3 ) Oliner , J. D. , Kinzler , K. W. , Meltzer , P. S. , George , D. L. and Vogelstein , B. Amplification of a gene encoding a p53‐associated protein in human sarcomas . Nature , 358 , 80 – 83 ( 1992 ). 1614537 4 ) Momand , J. , Zambetti , G. P. , Olson , D. C. , George , D. and Levine , A. J. The mdm‐2 oncogene product forms a complex with the p53 protein and inhibits p53–mediated trans‐activation . Cell , 69 , 1237 – 1245 ( 1992 ). 1535557 5 ) Kussie , P. H. , Gorina , S. , Marechal , V. , Elenbaas , B. , Moreau , J. , Levine , A. J. and Pavletich , N. P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain . Science , 274 , 948 – 953 ( 1996 ). 8875929 6 ) Boddy , M. N. , Freemont , P. S. and Borden , K. L. The p53–associated protein MDM2 contains a newly characterized zinc‐binding domain called the RING finger . Trends Biochem. Sci. , 19 , 198 – 199 ( 1994 ). 8048160 7 ) Haupt , Y. , Maya , R. , Kazaz , A. and Oren , M. Mdm2 promotes the rapid degradation of p53 . Nature , 387 , 296 – 299 ( 1997 ). 9153395 8 ) Kubbutat , M. H. , Jones , S. N. and Vousden , K. H. Regulation of p53 stability by Mdm2 . Nature , 387 , 299 – 303 ( 1997 ). 9153396 9 ) Barak , Y. , Juven , T. , Haffner , R. and Oren , M. mdm2 expression is induced by wild type p53 activity . EMBO J. , 12 , 461 – 468 ( 1993 ). 8440237 10 ) Xiao , Z. X. , Chen , J. , Levine , A. J. , Modjtahedi , N. , Xing , J. , Sellers , W. R. and Livingston , D. M. Interaction between the retinoblastoma protein and the oncoprotein MDM2 . Nature , 375 , 694 – 698 ( 1995 ). 7791904 11 ) Martin , K. , Trouche , D. , Hagemeier , C. , Sorensen , T. S. , LaThangue , N. B. and Kouzarides , T. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein . Nature , 375 , 691 – 694 ( 1995 ). 7791903 12 ) Marechal , V. , Elenbaas , B. , Piette , J. , Nicolas , J. C. and Levine , A. J. The ribosomal L5 protein is associated with mdm‐2 and mdm‐2‐p53 complexes . Mol. Cell. Biol. , 14 , 7414 – 7420 ( 1994 ). 7935455 13 ) Elenbaas , B. , Dobbelstein , M. , Roth , J. , Shenk , T. and Levine , A. J. The MDM2 oncoprotein binds specifically to RNA through its RING finger domain . Mol. Med. , 2 , 439 – 451 ( 1996 ). 8827714 14 ) Fiddler , T. A. , Smith , L. , Tapscott , S. J. and Thayer , M. J. Amplification of MDM2 inhibits MyoD‐mediated myogenesis . Mol. Cell. Biol. , 16 , 5048 – 5057 ( 1996 ). 8756663 15 ) Pomerantz , J. , Schreiber‐Agus , N. , Liegeois , N. J. , Silver‐man , A. , Alland , L. , Chin , L. , Potes , J. , Chen , K. , Orlow , I. , Lee , H. W. , Cordon‐Cardo , C. and DePinho , R. A. The Ink4a tumor suppressor gene product, p1 9Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53 . Cell , 92 , 713 – 723 ( 1998 ). 9529248 16 ) Zhang , Y. , Xiong , Y. and Yarbrough , W. G. ARF promotes MDM2 degradation and stabilizes p53: ARF‐INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways . Cell , 92 , 725 – 734 ( 1998 ). 9529249 17 ) Sigalas , I. , Calvert , A. H. , Anderson , J. J. , Neal , D. E. and Lunec , J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer . Nat. Med. , 2 , 912 – 917 ( 1996 ). 8705862 18 ) Matsumoto , R. , Tada , M. , Nozaki , M. , Zhang , C. L. , Sawamura , Y. and Abe , H. Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms . Cancer Res. , 58 , 609 – 613 ( 1998 ). 9485008 19 ) Cordon‐Cardo , C. , Latres , E. , Drobnjak , M. , Oliva , M. R. , Pollack , D. , Woodruff , J. M. , Marechal , V. , Chen , J. , Bren‐nan , M. F. and Levine , A. J. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas . Cancer Res. , 54 , 794 – 799 ( 1994 ). 8306343 20 ) McCann , A. H. , Kirley , A. , Carney , D. N. , Corbally , N. , Magee , H. M. , Keating , G. and Dervan , P. A. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status . Br. J. Cancer , 71 , 981 – 985 ( 1995 ). 7734324 21 ) Quesnel , B. , Preudhomme , C. , Fournier , J. , Fenaux , P. and Peyrat , J. P. MDM2 gene amplification in human breast cancer . Eur. J. Cancer , 30A, 982 , 984 ( 1994 ). 7946597 22 ) Inada , K. , Toi , M. , Yamamoto , Y. , Suzuki , A. , Kurisaki , T. , Suzuki , H. and Tominaga , T. Immunocytochemical analysis of MDM2 protein expression and its relevance to tumor angiogenesis in primary breast cancer . Oncol. Rep. , 3 , 667 – 671 ( 1996 ). 21594432 23 ) Hideshima , T. , Shinohara , T. , Baba , M. and Shirakusa , T. The expression of MDM2 and p53 protein in breast carcinoma . Oncol. Rep. , 4 , 297 – 300 ( 1997 ). 21590046 24 ) Baunoch , D. A. , Watkins , L. F. , Tewari , A. , Reece , M. T. , Adams , L. , Stack , R. , Brown , A. , Jones , L. , Christian , D. , Latif , N. A. , Lawrence , W. D. and Lane , M. A. MDM2 overexpression in benign and malignant lesions of the human breast: association with ER expression . Int. J. Oncol. , 8 , 895 – 899 ( 1996 ). 21544443 25 ) Marchetti , A. , Buttitta , F. , Girlando , S. , Dalla Palma , P. , Pellegrini , S. , Fina , P. , Doglioni , C. , Bevilacqua , G. and Barbareschi , M. mdm2 gene alterations and mdm2 protein expression in breast carcinomas . J. Pathol. , 175 , 31 – 38 ( 1995 ). 7891224 26 ) Gudas , J. M. , Nguyen , H. , Kiein , R. C. , Katayose , D. , Seth , P. and Cowan , K. H. Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells . Clin. Cancer Res. , 1 , 71 – 80 ( 1995 ). 9815889 27 ) Roemer , K. and Friedmann , T. Modulation of cell proliferation and gene expression by a p53–estrogen receptor hybrid protein . Proc. Natl. Acad. Sci. USA , 90 , 9252 – 9256 ( 1993 ). 8415687 28 ) Suzuki , A. , Toi , M. , Yamamoto , Y. , Saji , S. , Muta , M. and Tominaga , T. Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma . Jpn. J. Cancer Res. , 89 , 221 – 227 ( 1998 ). 9548451 29 ) Chen , L. , Agrawal , S. , Zhou , W. , Zhang , R. and Chen , J. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage . Proc. Natl. Acad. Sci. USA , 95 , 195 – 200 ( 1998 ). 9419352 30 ) El‐Deiry , W. S. , Tokino , T. , Velculescu , V. E. , Levy , D. B. , Parsons , R. , Trent , J. M. , Lin , D. , Mercer , W. E. , Kinzler , K. W. and Vogelstein , B. WAF1, a potential mediator of p53 tumor suppression . Cell , 75 , 817 – 825 ( 1993 ). 8242752 31 ) Harper , J. W. , Adami , G. R. , Wei , N. , Keyomarsi , K. and Elledge , S. J. The p21 Cdk‐interacting protein Cip1 is a potent inhibitor of G1 cyclin‐dependent kinases . Cell , 75 , 805 – 816 ( 1993 ). 8242751 32 ) Dulic , V. , Kaufmann , W. K. , Wilson , S. J. , Tlsty , T. D. , Lees , E. , Harper , J. W. , Elledge , S. J. and Reed , S. I. p53–dependent inhibition of cyclin‐dependent kinase activities in human fibroblasts during radiation‐induced G1 arrest . Cell , 76 , 1013 – 1023 ( 1994 ). 8137420 33 ) Hurd , C. , Khattree , N. , Alban , P. , Nag , K. , Jhanwar , S. C. , Dinda , S. and Moudgil , V. K. Hormonal regulation of the p53 tumor suppressor protein in T47D human breast carcinoma cell line . J. Biol. Chem. , 270 , 28507 – 28510 ( 1995 ). 7499360 34 ) Hurd , C. , Khattree , N. , Dinda , S. , Alban , P. and Moudgil , V. K. Regulation of tumor suppressor proteins, p53 and retinoblastoma by estrogen and antiestrogens in breast cancer cells . Oncogene , 15 , 991 – 995 ( 1997 ). 9285694 35 ) Yu , C. L. , Driggers , P. , Barrera‐Hernandez , G. , Nunez , S. B. , Segars , J. H. and Cheng , S. The tumor suppressor p53 is a negative regulator of estrogen receptor signaling pathways . Biochem. Biophys. Res. Commun. , 239 , 617 – 620 ( 1997 ). 9344880 36 ) Hall , P. A. , McKee , P. H. , Menage , H. D. , Dover , R. and Lane , D. P. High levels of p53 protein in UV‐irradiated normal human skin . Oncogene , 8 , 203 – 207 ( 1993 ). 8093810 37 ) Zhan , Q. , Carrier , F. and Fornace , A. J. , Jr. Induction of cellular p53 activity by DNA‐damaging agents and growth arrest . Mol. Cell. Biol. , 13 , 4242 – 4250 ( 1993 ). 8321226 38 ) Perry , M. E. , Piette , J. , Zawadzki , J. A. , Harvey , D. and Levine , A. J. The mdm‐2 gene is induced in response to UV light in a p53–dependent manner . Proc. Natl. Acad. Sci. USA , 90 , 11623 – 11627 ( 1993 ). 8265599 39 ) Lianes , P. , Orlow , I. , Zhang , Z. F. , Oliva , M. R. , Sarkis , A. S. , Reuter , V. E. and Cordon‐Cardo , C. Altered patterns of MDM2 and TP53 expression in human bladder cancer . J. Natl. Cancer Inst. , 86 , 1325 – 1330 ( 1994 ). 8064890 40 ) Riou , G. , Barrois , M. , Prost , S. , Terrier , M. J. , Theodore , C. and Levine , A. J. The p53 and mdm‐2 genes in human testicular germ‐cell tumors . Mol. Carcinog. , 12 , 124 – 131 ( 1995 ). 7893365 41 ) Maestro , R. , Gloghini , A. , Doglioni , C. , Gasparotto , D. , Vukosavljevic , T. , De Re , V. , Laurino , L. , Carbone , A. and Boiocchi , M. MDM2 overexpression does not account for stabilization of wild‐type p53 protein in non‐Hodgkin's lymphomas . Blood , 85 , 3239 – 3246 ( 1995 ). 7756655 42 ) Landers , J. E. , Cassel , S. L. and George , D. L. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild‐type p53 protein . Cancer Res. , 57 , 3562 – 3568 ( 1997 ). 9270029 43 ) Landers , J. E. , Haines , D. S. , Strauss , J. F. , 3rd and George , D. L. Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells . Oncogene , 9 , 2745 – 2750 ( 1994 ). 8058341 44 ) Keleti , J. , Quezado , M. M. , Abaza , M. M. , Raffeld , M. and Tsokos , M. The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild‐type p53 protein . Am. J. Pathol. , 49 , 143 – 151 ( 1996 ). 45 ) Zou , M. , Shi , Y. , Al‐Sedairy , S. , Hussain , S. S. and Farid , N. R. The expression of the MDM2 gene, a p53 binding protein, in thyroid carcinogenesis . Cancer , 76 , 314 – 318 ( 1995 ). 8625108 46 ) Gunther , T. , Schneider‐Stock , R. , Rys , J. , Niezabitowski , A. and Roessner , A. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico‐pathological factors . J. Cancer Res. Clin. Oncol. , 123 , 388 – 394 ( 1997 ). 9260591 47 ) Bull , E. K. , Chakrabarty , S. , Brodsky , I. and Haines , D. S. mdm2–P2 transcript levels predict the functional activity of the p53 tumor suppressor in primary leukemic cells . Oncogene , 16 , 2249 – 2257 ( 1998 ). 9619834 48 ) Borden , K. L. and Freemont , P. S. The RING finger domain: a recent example of a sequence‐structure family . Curr. Opin. Struct. Biol. , 6 , 395 – 401 ( 1996 ). 8804826 49 ) Saurin , A. J. , Hamlett , J. , Clague , M. J. and Pennington , S. R. Inhibition of mitogen‐induced DNA synthesis by bafilomycin A1 in Swiss 3T3 fibroblasts . Biochem. J. , 313 , 65 – 70 ( 1996 ). 8546711",
  "plain_text": "The overexpression of the oncogene product MDM2 is often observed in human breast cancer cells, especially in estrogen receptor (ER)‐positive ones. To study the role of MDM2 protein in ER‐positive breast cancer, we have established cell lines derived from MCF‐7 which stably express increased and decreased levels of MDM2 by transfection of a mammalian expression vector containing human mdm2 cDNA in sense and antisense orientations, respectively. Interestingly, MDM2 overexpression in MCF‐7 cells afforded a remarkable growth advantage under estradiol (E2)‐sup‐plemented condition. Then, we analyzed the expression of p53, which is an important regulator of growth and the cell cycle. Unexpectedly, the p53 accumulation induced by E2 was remarkably higher in MCF‐7 cells stably overexpressing MDM2 than in the parent MCF‐7 cells. On the other hand, reduction of MDM2 suppressed the E2‐induced increase in p53 protein. Moreover, mdm2 antisense oligonucleotides prevented E 2 ‐induced accumulation of p53. In the steady state, the cellular levels of p53 were also correlated with those of MDM2. These interactions are not consistent with the well‐known role of MDM2, which acts as a negative regulator for p53 by inhibiting its function and promoting its rapid degradation. These results suggest that MDM2 may regulate the expression of p53 in the steady state and in response to E2 in breast cancer cells, and imply a novel and important role of MDM2 during breast carcinogenesis."
}
